One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Vertex Pharmaceuticals Inc (VRTX) News
Latest headlines that mention VRTX, newest first · each headline opens the original publisher
- Last price
- $503.25
- Day change
- -0.47%
- Next earnings
- 2026-11-02
VRTX headlines
last 30 daysVertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Temasek-backed Vertex Ventures Japan has invested in Heartbeats, a Tokyo-based digital trading cards company, the latest in a series of bets aimed at turning Japanese startups into global unicorns.
This biotech player is firing on all cylinders.
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs. The post The Surprise That Sent Vertex — And Its Chief Rival — Soaring appeared first on Investor's Business Daily .
Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex. The post Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened? appeared first on Investor's Business Daily .
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Also mentioned with VRTX
30dHeadlines that tag both tickers
VRTX news alerts
Get an alert by email or push when a new headline mentions VRTX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.